Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays ...

Gemogenovatucel-T is a DNA-engineered, triple-function immunotherapy that utilizes a patient's autologous tumor cells as a source for the complete matrix of tumor-related clonal signals. Its mechanism ...

A team of researchers from the Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER) and the University of Seville, in collaboration with the Virgen Macarena University Hospital, ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today ...

A team of researchers have identified a fundamental mechanism that links the 24-hour circadian cycle to the precise repair of ...

Ovarian cancer standard of care has not advanced in over 30 years, but a new DNA-based immunotherapy could be a gamechanger, showing major survival gains in clinical trials.

Recent clinical developments in the treatment of platinum-resistant ovarian cancer (PROC) have introduced several novel therapeutic classes, including selective glucocorticoid receptor antagonists, ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...